---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-328470"
form_type: "8-K/A"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2026-07-31T20:05:13+00:00"
generated_at: "2026-07-31T20:06:13.291751+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Neurocrine files pro forma financials for Soleno acquisition; combined net income $294M for H1 2026

## Summary
- Pro forma combined net income $294.0M ($2.92 basic EPS) for six months ended June 30, 2026.
- Pro forma combined net income $324.5M ($3.26 basic EPS) for year ended Dec 31, 2025.
- Acquisition of Soleno for $53/share added VYKAT XR for Prader-Willi syndrome; funded with $600M credit facility draw, fully repaid by June 30.
- Soleno contributed $94.6M revenue in Q1 2026 and $190.4M in FY2025.
- Preliminary purchase price allocation includes $168.2M inventory step-up amortized over 4-6 years.

## SEC filing metadata
- accession: 0001193125-26-328470
- form_type: 8-K/A
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2026-07-31T20:05:13+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000119312526328470/0001193125-26-328470-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000119312526328470/d73154d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-328470
- JSON: https://secwatch.observer/filing/0001193125-26-328470.json
- Plain text: https://secwatch.observer/filing/0001193125-26-328470.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.